- $12.70m
- $61.45m
- €47.47m
- 28
- 60
- 17
- 27
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.24 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -81.43% | ||
| Return on Equity | -1362.71% | ||
| Operating Margin | -72.25% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 40.48 | 48.78 | 38.45 | 42.23 | 47.47 | 48.57 | 59.44 | 8.42% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Centogene N.V., is a commercial company. The company focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The company's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Company's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.
Directors
- Peer Schatz CSU (55)
- Andrin Oswald CEO (50)
- Richard Stoffelen CFO (53)
- Volkmar Weckesser CIO (53)
- Philip Lambert CSO (53)
- Sun Kim DIR (49)
- Peter Bauer OTH (51)
- Michael Motz OTH
- Hubert Birner IND (54)
- Berndt Modig IND (62)
- Guido Prehn IND (43)
- Jonathan Sheldon IND (49)
- Eric Souetre IND (65)
- Holger Friedrich SUB (55)
- Flemming Ornskov SUB (63)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- October 11th, 2018
- Public Since
- November 7th, 2019
- No. of Employees
- 517
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 27,865,752
- Address
- Am Strande 7, ROSTOCK, 18055
- Web
- https://www.centogene.com/
- Phone
- +49 38180113400
- Auditors
- Ernst & Young GmbH
Upcoming Events for CNTG
Q3 2023 Centogene NV Earnings Release
Centogene NV Annual Shareholders Meeting
Similar to CNTG
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Centogene NV share price?
As of Today at 19:05 UTC, shares in Centogene NV are trading at $0.46. This share price information is delayed by 15 minutes.
How has the Centogene NV share price performed this year?
Shares in Centogene NV last closed at $0.46 and the price had moved by -37.59% over the past 365 days. In terms of relative price strength the Centogene NV share price has underperformed the S&P500 Index by -48.07% over the past year.
What are the analyst and broker recommendations for Centogene NV?
The overall consensus recommendation for Centogene NV is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Centogene NV dividend yield?
Centogene NV does not currently pay a dividend.
Does Centogene NV pay a dividend?
Centogene NV does not currently pay a dividend.
When does Centogene NV next pay dividends?
Centogene NV does not currently pay a dividend.
How do I buy Centogene NV shares?
To buy shares in Centogene NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Centogene NV?
As of the previous close price of $0.46, shares in Centogene NV had a market capitalisation of $12.70m.
Where are Centogene NV shares listed?
Here are the trading details for Centogene NV:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CNTG
What kind of share is Centogene NV?
Based on an overall assessment of its quality, value and momentum Centogene NV is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Centogene NV share price forecast for 2024?
The analyst consensus target price for shares in Centogene NV is $1.50. That is 229.16% above the last closing price of $0.46.
Analysts covering Centogene NV currently have a consensus Earnings Per Share (EPS) forecast of -€1.60 for the next financial year.
What is the trend in the Centogene NV share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Centogene NV. Over the past six months, its share price has underperformed the S&P500 Index by -62.05%.
As of the last closing price of $0.46, shares in Centogene NV were trading -56.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Centogene NV PE Ratio?
The Centogene NV PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.46.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Centogene NV?
Centogene NV's management team is headed by:
- Peer Schatz - CSU
- Andrin Oswald - CEO
- Richard Stoffelen - CFO
- Volkmar Weckesser - CIO
- Philip Lambert - CSO
- Sun Kim - DIR
- Peter Bauer - OTH
- Michael Motz - OTH
- Hubert Birner - IND
- Berndt Modig - IND
- Guido Prehn - IND
- Jonathan Sheldon - IND
- Eric Souetre - IND
- Holger Friedrich - SUB
- Flemming Ornskov - SUB